The first detailed look at data on Amgen Inc.¡¯s obesity drug offers a promising glimpse into the future of weight-loss treatment.
How promising? Sure, it¡¯s early days, but that hasn¡¯t stopped investors from talking up its blockbuster potential. They may turn out to be right.
The weight loss industry has undergone a sea change in recent years. Treatments such as Novo Nordisk A/S¡¯s Wegovy, approved in 2021, and Eli Lilly & Co.¡¯s tirzepatide, likely to be approved next year, are allowing people to shed many more pounds than any of the options that came before them. Tirzepatide induced an average 20% reduction in body weight in its Phase 3 study ¡ª an amount that starts to put it in a category that compares to bariatric surgery.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.